long intergenic non-protein coding RNA 2261Genealiases: []
Q-omics provides the consensus-scored LINC02261 profile across patient tissues and cancer cell-line models. LINC02261 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LINC02261 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, LINC02261 RNA expression shows 5,606 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, COAD, and STAD as cancer lineages where LINC02261 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02261 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02261 survival associations across molecular data types. LINC02261 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02261 RNA expression–survival associations across cancer types. High LINC02261 expression shows unfavorable associations in KIRP, LIHC, LUAD, HNSC, SARC and READ. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LINC02261 RNA expression.
This table summarizes LINC02261 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02261. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02261 shows lower tumor expression in COAD, KIRC, READ and BRCA and higher tumor expression in KICH and HNSC. The COAD box plot shows higher LINC02261 RNA expression in normal versus tumor tissue (log2 FC = −0.135, t-test p < 0.001).
This table shows molecular features associated with LINC02261 in patient tissues and cancer cell lines. In patient samples, LINC02261 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
